When it comes to small-cap investing, patience is always key.
For the longest time, no one thought much of Amazon.com (AMZN) at less than $10 a share.
Now it’s up to $2,039 a share.
Microsoft (MSFT) once traded at less than $15. It’s now over $111.
Point being – if you know you’ve found a clear winner, hold onto it for the long haul. Even if there’s selling pressure along the way, don’t feel forced into selling. Simply hold.
That’s what we did with Endocyte Inc. (ECYT), for example.
When we first spotted the development-stage biotech stock in May 2015, it traded at just $6.30 a share after plunging from $34. But with a significant amount of cash on hand, and several products in various stages of FDA trials, we knew we had a potential winner on our hands.
We would recommend it again at $2.86 a share in October 2016.
We recommended it a third time at $1.43 a share. Even though the stock continued to drop from its lofty high of $34, fundamentals remained strong.
All may have seemed lost to most shareholders. But we held on.
And it’s a good thing we did.
The stock just hit a high of $20.85 for potential returns of 231%, 629%, and 1,358% respectively.
As it turns out, we had quite a winner on our hands.
By October 2017, the stock began to move higher and never looked back.
At that time, the company had just announced the completion of an exclusive worldwide license of PSMA-617 from ABX GmbH. From there, the company moved quickly into Phase 3 development of Lu-PSMA-617, a radioligand therapeutic (RLT) that targets the prostate-specific membrane antigen (PSMA), present in approximately 80% of patients with metastatic castration-resistant prostate cancer.
That license gave it access to a $1 billion opportunity.
Mike Sherman, Endocyte’s president and CEO, says the deal with Germany’s ABX GmbH gives it a drug candidate that seems to be “profoundly better than anything we’ve seen” in metastatic castration-resistant prostate cancer.
“Approximately 80,000 patients are potential candidates for Lu-PSMA-617 in the late stages of the disease, and this is just in major markets,” he told FierceBiotech. “That’s about a $5 billion market, assuming a price near that of similar therapies. As potentially first to market with a PSMA-targeted agent, we clearly see this opportunity as greater than $1 billion.”
In short, when you know you’ve found a winner with strong fundamentals, buy it and have patience This one produced a win of up to 1,358% in just months.